Transmedics Group Inc expected to post a loss of 3 cents a share - Earnings Preview

TransMedics

24/02/2024 01:20

* Transmedics Group Inc  TMDX.OQ   TMDX.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
26 for the period ending December 31 2023
    * The Andover Massachusetts-based  company is expected to
report a
118.3% increase in revenue to $68.507 million from $31.38
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Transmedics Group Inc is
for a
loss of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Transmedics
Group
Inc is $92.00​, above​ its last closing price of $83.14. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.16       -0.16      -0.78     Missed  -382.5
 Jun. 30 2023  -0.11       -0.13      -0.03     Beat    76.9
 Mar. 31 2023  -0.21       -0.25      -0.08     Beat    67.5​
 Dec. 31 2022  -0.30       -0.30      -0.21     Beat    30
 ​​Sep.        -0.43       -0.41      -0.25     Beat    39.3
 30 2022                                                
 Jun. 30 2022  -0.35       -0.35      -0.41     Missed  -17.8​
 Mar. 31 2022  -0.39       -0.38      -0.38     Met     0
 Dec. 31 2021  -0.43       -0.42      -0.46     Missed  -8.5
 This summary was machine generated February 24 at 01:20 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)